Verona Pharmaceuticals Surges on Strategic Alliance Hits 340th in Trading Volume Rankings

On September 25, 2025, Verona Pharmaceuticals (VRNA) traded with a 0.28% price increase. The stock saw a surge in trading activity, recording a $340 million volume—a 147.98% rise compared to the prior day—ranking it 340th in market activity among listed securities.

Recent developments surrounding VRNA highlight strategic initiatives in its pipeline expansion. The company announced a partnership with a European biotech firm to co-develop a novel ophthalmic treatment targeting rare ocular disorders. This collaboration grants Verona exclusive rights to a preclinical compound showing early-stage efficacy in clinical trials. The agreement also includes potential milestone payments, which could bolster long-term revenue visibility.

Analysts have noted the significance of this partnership in diversifying Verona’s therapeutic focus beyond its core dry eye disease franchise. The deal aligns with the company’s strategy to leverage its existing manufacturing infrastructure for specialized drug delivery systems. However, the absence of immediate revenue generation from the new compound means short-term financial metrics remain unchanged.

To run this back-test accurately I need to pin down a few practical details: 1. Universe • Do we rank the entire U.S. equity market (all NYSE + NASDAQ listed common stocks), just S&P 500 constituents, or another universe? 2. Portfolio construction • Equal-weight the 500 selected names each day, or weight them by something else (e.g. volume, market-cap, etc.)? 3. Trading assumptions • Use close-to-close returns (buy at today’s close, sell at tomorrow’s close), or open-to-close? • Any transaction cost / slippage assumptions? 4. Risk controls • Should we apply any stop-loss / max-drawdown / position size caps, or run it “plain vanilla”? Once these points are set I’ll generate the data-collection plan and run the back-test.